KCT0003951尚未招募未知
A 12-week, randomized, double-blind, parallel placebo-controlled human trial to evaluate the efficacy and safety of Omija single extract on body fat
Wonkwang University, Gwangju Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Adults over 19 years
- •2. BMI of 23 kg/m2 or higher at the time of screening, with a body fat rate of 25 % for males and 30% for females
- •3. Those who have heard the full explanation of this human application test, fully understand it, and have voluntarily decided to participate and have agreed in writing to comply with the precautions.
排除标准
- •1. Those who have lost more than 10% of their weight within 3 months prior to screening
- •2. high obesity(BMI over 35 kg/m2)
- •3. Products that affect weight within one month of the screening test are being taken (concomitant medication references) with improved body fat health food or medicines, contraceptives, steroids, and female hormones).
- •4. Persons with clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, interdialogal system, kidney and urinary machinery, nervous system, musculoskeletal system, inflammatory and blood tumor disease, gastrointestinal diseases, etc.
- •5. Diabetic patients with oral hypoglycemic agents or insulin injections (as at the time of the subject's screening)
- •6. A person who has a history of clinically significant hypersensitivity in the ingredient of Omija.
- •7. Those who have had experience in antipsychotic medication within three months prior to screening.
- •8. Those who participated in other human application tests within 3 months prior to the screening test.
- •9. Someone who has or is suspected of drug or alchol abuse.
- •10. A menopause woman
- •11. A pregnant or breast-feeding woman.
- •12. where appropriate contraception has not been accepted among fertile women.
- •13. Diagnostic test A person who is determined by the Principal inspector to be ineligible for research due to medical examination results or other reasons
研究者
相似试验
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension - non aplicableHypertensionEUCTR2004-002252-33-ESovartis Farmacéutica S.A672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertensioHypertensionEUCTR2004-002252-33-DEovartis Pharma Services AG672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.hypertensionEUCTR2008-007831-41-GBovartis Pharma Services AG790
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2008-007831-41-SKovartis Pharma Services AG790
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.hypertensionEUCTR2008-007831-41-HUovartis Pharma Services AG790